Follow your passion..Dream a career.. !

Course Details

Course Name

MSc by Research Health Economics

Level of study

Postgraduate Taught

Study Mode

Fulltime

Duration

1 Years

Start Term

Sept

Country

United Kingdom

City

North Wales

Course Subject

Medicine & Health

Course Fees

Inside EU: 6950

Outside EU: 14800

Universities

Bangor University

Description

The MSc in Health Economics by Research programme will provide a dedicated route for high calibre students who (may have a specific research aim in mind and) are ready to carry out independent research leading to PhD level study. Alternatively it would be appropriate for students who are seeking a stand-alone research based qualification suitable for a career in research with transferable skills for graduate employment.

It is also suitable for individuals seeking to gain a formal qualification while continuing to work full-time. We offer a fully flexible study programme for full-time or part-time study, on campus or by e-learning. Our aim is to help professionals working in the area of health economics accelerate their existing careers by exploring new options within pharmacoeconomics, healthcare policy or public health economics and expanding their existing set of skills.

Research topics

CHEME is involved in a wide range of health economics activities. This section relates to some key research topics, that you may be interested in completing a project on:

Pharmacoeconomics

Cost effectiveness analysis of medicines, pharmacogenetics, pharmaceutical services
Pharmaceutical policy, medicines use
Methods of economic evaluation and health technology assessment

Public health economics

Valuing nature, public health and the circular economy
Behavioural economics, public health and health policy
Application of cost benefit analysis and social return on investment analysis in public health

For further information on our research activities please see our website http://cheme.bangor.ac.uk/researchprojects.php.en

Some suggested projects by members of our research staff are listed below:

Pharmacoeconomics:

Health technology assessment

Measurement of resource use and cost – review and analysis of patient-reported and routinely collected data
Analysis of resource use datasets (medications, GP appointments, allied health, hospital appointments and admissions, Hospital Episode Statistics)
Review and analysis of methods of managing type 1 diabetes

Medication adherence

Impact of affordability on medication adherence
Methods to account for non-adherence in health economics analysis
Review and analysis of studies/trials which include a run-in period for assessing adherence

Pharmaceutical policy

Analysis of the approval, expenditure, cost-effectiveness, and confidential agreements relating to cancer drug treatments
Impact of incentives for drug development on cost-effectiveness

Public health economics:

Public health preventative strategies

Review and analysis of the multiplier effects on the economy of spending on health and social care
Analysis of the impacts of increased investment in housing to population health, NHS resource use and social care expenditure
Review the challenges of applying methods of economic evaluation to pragmatic public health research, and defining best practice
Assess the role of behavioural economics in promoting positive health-related behaviour change across the population

Investing in early years

Modelling the long-term impacts of increased early years investment across the life course
Assess the impact of school-based interventions using social return on investment methods

Valuing nature in public health

Assess methods of valuing nature in health economics and economic evaluation
Review and analysis of the impact of blue and green spaces on physical and mental health

Directors/ Supervisors

Supervision is provided by experienced health economists within the Centre for Health Economics and Medicines Evaluation including CHEME’s directors:

Professor Dyfrig Hughes leads the pharmacoeconomics theme, supported by staff with skills in health technology assessment, economic modelling, budget impact analysis, choice modelling, pharmaceutical policy, and trial-based economic evaluations.

Professor Rhiannon Tudor Edwards leads the public health economics theme, supported by staff with skills in economic evaluation including cost benefit analysis and social return on investment analysis, realist and systematic reviewing, programme budgeting and marginal analysis, and policy evaluation.

The Centre for Health Economics and Medicines Evaluation

The Centre for Health Economics and Medicines Evaluation (CHEME) was founded in 2001 and has grown to become one of the highest rated centres in the UK. At the last Research Excellence Framework, CHEME’s research outputs were rated 3rd out of 94 institutions across the UK.

CHEME researchers produce world-leading research across a wide range of health economic activities, which can be broadly categorised to: (i) economic evaluation alongside clinical trials; (ii) pharmacoeconomics; and (iii) public health economics. The Centre also has very close links with national organisations, including the National Health Service in the UK and advises on national policies.

Testimonial

“The Master’s by Research in Health Economics has enabled me to develop my quantitative, theoretical and analytical skills in an exciting area of healthcare. Specifically, offering me invaluable training in the application of pharmacoeconomics and introducing me to the concepts behind decision-making. I particularly enjoyed the flexibility of studying a research degree, the community environment within CHEME and working around top influencers within the field.”

Course is Available at :

Back

Notifications